- Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy: in a clinical trial, all 15 patients were alive and event-free at 20 months of age, as compared with a rate of survival of 8% in a historical cohort. http://www.nejm.org/doi/full/10.1056/nejmoa1706198 25 comments science
Linking pages
Related searches:
Search whole site: site:www.nejm.org
Search title: Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy | NEJM
See how to search.